IntelGenx Corp.

About Us

Technologies

Oral controlled-release drug delivery technologies have the ability to improve the performance of a wide variety of existing pharmaceutical compounds. The therapeutic effect of a drug compound will typically vary according to its bloodstream concentration. When the concentration is too low, efficacy may be reduced and when it is too high, side effects may increase.

Products

We are proud of our ability to provide and develop a wide and highly diverse range of products catering for present and future commercial needs. Our rapidly growing product pipeline consists of products at various stages of development from inception to commercialization. We are working closely with our partners in developing seven major products and are in negotiations to extend and develop partnerships for some of our other products.

Learn More Learn More

Stock Information

Latest News

  • 02/08/2010
    IntelGenx Receives FDA Complete Response Letter CPI-300
  • 01/25/2010
    IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm Technology
  • 01/21/2010
    IntelGenx Receives Notice of Allowance for Bupropion Patent
  • 01/11/2010
    IntelGenx Announces Manufacturing Site Change for CPI-300
  • 11/17/2009
    IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film
  • 11/10/2009
    IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009

News Archive »